Anxiety Disorder Treatment Market Research Report - Global Forecast till 2027

Global Anxiety Disorder Treatment Market Research Report: By Drug Class (SSRIs, SNRIs, TCAs, Pregabalin, Buspirone, Benzodiazepines, Moclobemide, Others) and By End-User (Hospitals, Mental Healthcare Centers, Asylums, Others) – Forecast to 2027

ID: MRFR/HC/6983-HCR | February 2021 | Region: Global | 100 pages

Anxiety Disorder Treatment Market Overview


Anxiety disorders account for a 8.60% share of the global disease burden. It includes panic disorders, post-traumatic stress disorder (PTSD), phobias, and obsessive-compulsive disorder. Anxiety disorders correspond with a high burden of illness as they are psychiatric disorders. Owing to increasing cases of anxiety disorders there is a need for the development of ingenious drugs for effective treatment. Additionally, various reimbursement policies present in developed countries for therapies and medication influences the market positively.


The anxiety disorder treatment market is expected to grow at a higher CAGR of 8.60% in the global market to account for the higher market value of approximately USD 16.96 million by the end of the forecasted period.


COVID 19 Analysis


The global pandemic of COVID 19 has affected a large section of society. Most of the people who had got Corona Virus is struggling with anxiety disorders. Owing to the increasing cases of generalized anxiety disorders, huge investments have been made by manufacturers for the development of anxiety disorder treatment. There are various types of anxiety disorders like agoraphobia, generalized anxiety disorder, and social anxiety disorder. This investment gives rise to increasing medication and hence increases the anxiety disorder treatment market size in the global market.


The global pandemic of COVID 19 has a positive effect on the global market share of this drug. The market share for this treatment is also expected to grow furthermore in the coming years.


Market Dynamics



  • Drivers


The rising number of anxiety disorders such as agoraphobia, generalized anxiety disorder, social anxiety disorder, and many others. This anxiety problem is most commonly prevailing in the US, affecting almost 40 million people who are above the age of 18 which increases the demand for effective treatment for these anxiety disorders. Also, the presence of reimbursement policies in various developed countries is another driving factor.



  • Opportunities


An increasing number geriatric population coupled with changing lifestyles are the main growth opportunities for the anxiety disorder treatment market. In the US major chunk of the population is aged above 65. It was found in studies that the chances of mental illness increase with the increase in age of an individual. They are more prone to psychological disorders. Also, the increasing advancement in technology is another growth opportunity.



  • Restraints


The anxiety disorder treatment market is flourishing all across the globe but some factor restricts its growth. One of the factors that hamper the market growth is the expiration of patents on branded medicines. Another factor is the presence of generic biosimilars which is a cost-effective alternative present introduced by various critical players. Biosimilars have reached the end of proprietary patents as it is a similar version of approved biologics which hampers the growth in the global market.


Value Chain Analysis


The anxiety disorder treatment market is growing rapidly in the global market owing to various benefits provided by it. It helps in providing relief during the pain caused by anxiety disorders. Also, different drugs class helps in treating different types of anxiety disorder problems. The Buspirone drug helps in treating generalized anxiety disorder. Moclobemide helps in treating anxiety disorders. Tricyclic Antidepressant affects brain chemicals for reducing symptoms of depression.


Anxiety Disorder Treatment Market Segmentation


The anxiety disorder treatment market has been divided all across the globe based on drug class and end-users.


Based on the Drug Class


The anxiety disorder treatment market has been divided all across the globe based on the drug class into moclobemide (helps in treating social anxiety and depression. This medicine is largely used in Western Europe especially in Australia, UK, and Canada. Though this medicine is not approved in the US), benzodiazepines (helps in treating anxiety), buspirone (helps in treating generalized anxiety disorder. This medicine is also known as anxiolytics), pregabalin (helps in treating epilepsy and generalized anxiety disorder. This medicine gives relief by sending pain signals towards the nervous system), Tricyclic Antidepressants (TCAs) (helps to ease depression symptoms by affecting brain chemicals), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (helps in reducing symptoms of depression symptoms, nerve pain, and anxiety disorders like sadness and irritability), and Selective Serotonin Reuptake Inhibitors (SSRIs) (these are commonly used as antidepressants for treating depressive disorders and anxiety disorders by blocking the reabsorption of serotonin in the brain. This treatment drug also has little side-effects).


Based on the End-Users


The anxiety disorder treatment market has been divided all across the globe based on the end-users into asylums (special institutions created for the special purpose of providing housing facilities for psychologically disorder people), mental healthcare centers (they provide a primary line of treatment and it is the most extensive care), hospitals, and many others. The largest market share is held by the hospital dividend owing to the increasing financing capabilities of the healthcare sector coupled with an increasing number of patients. The government of different regions is investing huge sums in improving the healthcare sector).


Anxiety Disorder Treatment Market Regional Analysis


The anxiety disorder treatment market has been divided all across the globe based on the region into the American region, European region, Asia-Pacific region, and the Middle East and African region. The largest market share is held by the American region owing to the increase in the number of anxiety disorder patients. The number of cases in the American region is increasing due to the stressful work environment and sedentary lifestyle.


The second-largest anxiety disorder treatment market share all across the globe is held by the European region owing to increasing awareness regarding the anxiety disorder problem and the availability of its effective treatment.


The third-largest anxiety disorder treatment market share all across the globe is held by the Asia-Pacific region owing to increasing generalized anxiety disorders coupled with psychological diseases which increases the demand for anxiety disorder treatment.


The Middle East and African region show a steady growth rate owing to small market size coupled with a lack of awareness regarding the availability of effective treatments for anxiety disorders in this region.


Anxiety Disorder Treatment Market Competitive Landscape


The most prominent major key players in the anxiety disorder treatment market all across the globe are mentioned below:



  • Bristol-Myers Squibb Company (US)

  • Lundbeck A/S (Denmark)

  • Johnson and Johnson (US)

  • GlaxoSmithKline PLC (UK)

  • Pfizer

  • Merck & Co.

  • Sanofi-Aventis (France)

  • AstraZeneca PLC (UK)

  • Forest Laboratories

  • Eli Lily and Company (US)


These major key players use various strategies to sustain their market position in the anxiety disorder treatment market in the global market by going for mergers, and acquisitions, by collaborating, setting up a new joint venture, establishing a partnership, developing a new production process, developing a new product line, innovation in the existing product, and many others to expand their customer base in the untapped market of the anxiety disorder treatment all across the globe.


Recent Developments



  • In December 2020, Cadent Therapeutics had been acquired by Novartis for a consideration of USD 770 million. It will help Novartis to broaden its presence in the mental health area by leveraging Cadent’s neuroscience portfolio.

  • In December 2020, NeuroRx merged with big rock partners acquisition corporation for developing therapies for COVID 19 and bipolar disorder. The combined value of the company will be around USD 500 million.

  • In August 2020, a new drug application (NDA) of esketamine has been approved by US FDA for treating depressive disorder (MDD).

  • In March 2020, results of the STRIDE-1 Phase 3 trial were disclosed significantly by Axsome Therapeutics Inc. for the treatment of resistant depression.


Anxiety Disorder Treatment Market Report Overview


This global anxiety disorder treatment market research report consists of the following elements mentioned below:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This market research report contains factors that drive the growth of the anxiety disorder treatment market in the global market along with the factors that restrict its growth in the global market. The opportunities available for growth during the forecasted period are mentioned. The impact of COVID 19 on the sales revenue of the anxiety disorder treatment market all across the globe is mentioned. The future growth rate during the forecasted period is estimated and mentioned.


Intended Audience


Anxiety disorder drugs manufacturing companies, research and development (R & D) companies, government organizations, healthcare organizations, healthcare providers, and many others.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 16.96 Million
  CAGR   8.60% (2021-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Eli Lilly and Company (US), Forest Laboratories, Inc. (US), AstraZeneca PLC (UK), Sanofi-Aventis (France), Merck & Co., Inc. (US), Pfizer, Inc. (US), GlaxoSmithKline PLC (UK), Johnson & Johnson (US), Lundbeck A/S (Denmark), Bristol-Myers Squibb Company (US)
  Key Market Opportunities   Rising prevalence of psychological diseases
  Key Market Drivers

  • Presence of favorable reimbursement policies in developed countries
  • Introduction of technologically advanced therapies


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The valuation of the global anxiety disorder treatment market had reached USD ~21,221.18 Million in 2021.

    The global anxiety disorder treatment market is projected to grow at approximately 5.4% CAGR during the forecast period (2021-2027).

    Presence of favorable reimbursement policies in developed countries.

    North America holds the largest share in the global anxiety disorder treatment market, followed by Europe and the Asia Pacific, respectively.

    Forest Laboratories, Inc. (US), Eli Lilly and Company (US), AstraZeneca PLC (UK), Merck & Co., Inc. (US), Sanofi-Aventis (France), Pfizer, Inc. (US), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Lundbeck A/S (Denmark), and Bristol-Myers Squibb Company (US), are some of the major players operating in the anxiety disorder treatment market.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.